The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Position in Breast Cancer Translational Research”
Reference: Ref. 30-2022
Application deadline: 15/08/2022
Number of vacancies: 1
Postdoctoral position available in the laboratory of Violeta Serra, PhD at the Vall d’Hebron Institute of Oncology, Barcelona, Spain. The project involves developing a clear understanding of the mechanisms of resistance to CDK4/6 inhibitors and to identify novel molecular biomarkers of drug response in vivo, as well as opportunities involving correlative science from clinical trials.
- PhD and/or MD with a strong background in molecular biology, biochemistry, cell biology and bioinformatics.
- Previous knowledge in liquid biopsy is required and at least one article as first author.
Please email a cover letter with scientific interests, CV, and names and contact information for 3 references to: email@example.com . Please use “Postdoctoral Position” as the subject line in your email.-
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.